Dark

ALPN
Alpine Immune Sciences, Inc. Common Stock
stock NASDAQ

Inactive

May 17, 2024

64.97USD+0.015%(+0.01)4,282,048

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-64.96)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

04:05PM EST Alpine Immune Sciences Announces Participation in January Investor Conferences Business Wire

Dec 16, 2021

08:25AM EST Why Alpine Immune Sciences Is Rising In Pre-market? RTTNews

08:07AM EST Alpine Immune Services, Horizon Therapeutics Report Exclusive License, Collab Deal To Develop Novel Protein-Based Therapies For Autoimmune, Inflammatory Diseases Benzinga

08:00AM EST Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases Business Wire

Nov 22, 2021

04:05PM EST Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference Business Wire

Nov 10, 2021

05:27PM EST Alpine Immune Sciences Q3 EPS $(0.55) Down From $(0.28) YoY, Sales $8.52M Up From $1.91M YoY Benzinga

04:05PM EST Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results Business Wire

Nov 8, 2021

08:05AM EST Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting Business Wire

Sep 25, 2021

10:56AM EDT Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More Benzinga

Sep 24, 2021

05:49AM EDT Alpine Immune Sciences Director Robert Conway Reported Purchase of 10,000 Shares @ Avg Price of $9.80/Share in Form 4 Filing on Thursday Benzinga

Sep 22, 2021

10:47AM EDT Shares of Alpine Immune Sciences, Inc. (ALPN) are gaining nearly 13% on Wednesday morning despite no stock-related news to drive the shares. RTTNews

05:55AM EDT Alpine Immune Sciences Director Xiangmin Cui Reported Purchase of 1,542,553 Shares @ Avg Price of $9.40/Share in Form 4 Filing on Tuesday Benzinga

Sep 21, 2021

10:48AM EDT Alpine Immune Sciences Earnings Perspective: Return On Capital Employed Benzinga

Sep 15, 2021

08:08AM EDT Alpine Immune Sciences Announces $91M Private Placement Benzinga

08:05AM EDT Alpine Immune Sciences Announces $91 Million Private Placement Business Wire

Sep 7, 2021

04:05PM EDT Alpine Immune Sciences Announces Participation in September Investor Conferences Business Wire

Aug 10, 2021

04:53PM EDT Alpine Immune Sciences: Q2 Earnings Insights Benzinga

04:24PM EDT Alpine Immune Sciences Q2 EPS $(0.46) Misses $(0.40) Estimate, Sales $7.19M Beat $6.48M Estimate Benzinga

04:06PM EDT Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results Business Wire

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

08:00AM EDT Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences Business Wire

Jul 2, 2021

04:25PM EDT Alpine Immune Sciences Says Entered Into Sales Agreement With Cowen And Company; Says Under Agreement, May Offer, Sell Common Stock Of Up To $75M From Time To Time Through Cowen Acting As Agent Benzinga

Jun 30, 2021

11:17AM EDT Alpine Immune Sciences Initiates Trial Collaboration With Merck Benzinga

08:30AM EDT Alpine Immune Sciences To Collaborate With Merck On Immuno-Oncology Study To Evaluate ALPN-202 In Combination With KEYTRUDA (pembrolizumab) Benzinga

08:12AM EDT Alpine Immune Sciences Teams With Merck On Immuno-Oncology Study To Evaluate ALPN-202 In Combination With KEYTRUDA RTTNews

08:00AM EDT Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA(r) (pembrolizumab) Business Wire

Jun 24, 2021

08:07AM EDT Alpine Immune Sciences Doses First Patient In Synergy, A Phase 2 study Of ALPN-101 In Systemic Lupus Erythematosus RTTNews

08:04AM EDT Alpine Immune Sciences Reports First Patient Dosed In Its ALPN-101 Phase 2 Lupus Trial; Reports $45M Development Milestone Payment Benzinga

08:00AM EDT Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration Business Wire

Jun 9, 2021

04:49PM EDT Alpine Immune Sciences Publishes Study Titled 'ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2)' To ClinicalTrials.Gov Site Benzinga

Jun 8, 2021

08:11AM EDT Alpine Immune Sciences To Join Russell 3000 Index, Effective Jun. 28 Benzinga

08:00AM EDT Alpine Immune Sciences Set to Join Russell 3000(r) Index Business Wire

Jun 4, 2021

04:08PM EDT Alpine Immune Sciences Highlights ALPN-202 Data Presented At American Society Of Clinical Oncology Jun. 4 At 7 p.m. EDT Benzinga

04:05PM EDT Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting Business Wire

Jun 3, 2021

08:14AM EDT Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies Benzinga

Jun 2, 2021

04:06PM EDT Alpine Immune Sciences Says Presents ALPN-303 Data During 2021 EULAR Virtual Meeting Benzinga

04:05PM EDT Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting Business Wire

08:00AM EDT Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer Business Wire

May 19, 2021

05:10PM EDT Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting Business Wire

May 18, 2021

04:06PM EDT Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting Business Wire

May 14, 2021

06:06AM EDT Alpine Immune Sciences S-3 Filing Shows Registration For $150M Mixed Securities Shelf Offering Benzinga

May 13, 2021

04:26PM EDT Alpine Immune Sciences Q1 EPS $(0.45) Down From $(0.30) YoY, Sales $3.20M Up From $1.09M YoY Benzinga

04:05PM EDT Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results Business Wire

Apr 28, 2021

04:05PM EDT Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting Business Wire

Apr 12, 2021

08:24AM EDT Alpine Immune Sciences Presents Clinical And Preclinical Oncology Program Updates At AACR RTTNews

08:11AM EDT Alpine Immune Sciences To Present Clinical And Preclinical Oncology Program Updates At AACR Virtual Annual Meeting I Benzinga

Mar 19, 2021

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

Mar 18, 2021

04:18PM EDT Alpine Immune Sciences Q4 EPS $(0.27) Beats $(0.31) Estimate, Sales $5.64M Beat $2.59M Estimate Benzinga

04:05PM EDT Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

07:07AM EDT Earnings Scheduled For March 18, 2021 Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 11, 2021

04:05PM EST Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Business Wire

Mar 10, 2021

04:35PM EST Alpine Immune Sciences Highlights Poster Presentations At American Association For Cancer Research Apr. 10 Benzinga

04:30PM EST Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I Business Wire

Feb 22, 2021

04:05PM EST Alpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences Business Wire

Jan 6, 2021

08:18AM EST Alpine Immune Sciences Appoints Pamela Holland SVP, Research RTTNews

08:00AM EST Alpine Immune Sciences Announces Executive Leadership Addition and Promotion Business Wire

Dec 23, 2020

04:11PM EST Avidity Partners Management Reports In 13G Filing A 5.6% Stake In Alpine Immune Sciences Benzinga

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 21, 2020 Benzinga

08:07AM EST HC Wainwright & Co. Initiates Coverage On Alpine Immune Sciences with Buy Rating, Announces Price Target of $21 Benzinga

Dec 17, 2020

08:00AM EST Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 11, 2020

08:16AM EST Natasha Hernday Joins Alpine's Board RTTNews

08:00AM EST Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors Business Wire

Nov 24, 2020

04:08PM EST Alpine Immune Sciences To Participate In Fireside Chat At The Evercore ISI 3rd Annual HealthCONx Virtual Conference Dec. 3 Benzinga

04:05PM EST Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference Business Wire

Nov 16, 2020

04:05PM EST Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire

Nov 12, 2020

04:16PM EST Alpine Immune Sciences Q3 EPS $(0.28) Misses $(0.23) Estimate, Sales $1.91M Up From $289.00K YoY Benzinga

04:05PM EST Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update Business Wire

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

04:05PM EST Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update Business Wire

Sep 15, 2020

04:05PM EDT Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Wire

Sep 8, 2020

04:05PM EDT Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire

Aug 26, 2020

09:42AM EDT Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga

07:11AM EDT Cowen & Co. Initiates Coverage On Alpine Immune Sciences with Outperform Rating Benzinga

Aug 12, 2020

10:05AM EDT Piper Sandler Maintains Overweight on Alpine Immune Sciences, Lowers Price Target to $18 Benzinga

Aug 11, 2020

04:19PM EDT Alpine Immune Sciences Q2 EPS $(0.53) Up From $(0.64) YoY, Sales $688.00K Up From $567.00K YoY Benzinga

04:05PM EDT Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire

04:02AM EDT Earnings Scheduled For August 11, 2020 Benzinga

Aug 5, 2020

04:06PM EDT Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire

Aug 4, 2020

04:05PM EDT Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update Business Wire

Jul 24, 2020

09:23AM EDT Alpine Immune Sciences Announces $60 Mln Private Placement RTTNews

09:15AM EDT Alpine Immune Sciences Reports $60M Private Placement Benzinga

09:15AM EDT Alpine Immune Sciences Announces $60 Million Private Placement Business Wire